Picture of Vericel logo

VCEL — Vericel Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapFalling Star

Momentum

Relative Strength (%)
1m-18.66%
3m-12.2%
6m-21.21%
1yr-38.67%
Volume Change (%)
10d/3m+15.07%
Price vs... (%)
52w High-58.95%
50d MA-17.8%
200d MA-31.78%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-5.41%
Return on Equity-7.21%
Operating Margin-7.5%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Vericel EPS forecast chart

Profile Summary

Vericel Corporation is a commercial-stage biopharmaceutical company. The Company is focused on therapies for the sports medicine and severe burn care markets. It markets two autologous cell therapy products in the United States, which include MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel is a permanent skin replacement humanitarian use device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area (TBSA). Its NexoBrid, is a registration-stage, topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
March 24th, 1989
Public Since
February 4th, 1997
No. of Shareholders
169
No. of Employees
281
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
47,119,902
Blurred out image of a map
Address
64 Sidney St, CAMBRIDGE, 02139-4170
Web
https://vcel.com/
Phone
+1 7349305555
Auditors
PricewaterhouseCoopers LLP

VCEL Share Price Performance

Upcoming Events for VCEL

Q2 2022 Vericel Corp Earnings Release

Q3 2022 Vericel Corp Earnings Release

Similar to VCEL

Picture of Aadi Bioscience logo

Aadi Bioscience

us flag iconNASDAQ Capital Market

Picture of Acasti Pharma logo

Acasti Pharma

us flag iconNASDAQ Capital Market

Picture of Adamis Pharmaceuticals logo

Adamis Pharmaceuticals

us flag iconNASDAQ Capital Market

Affinia Therapeutics

us flag iconNASDAQ Capital Market

Agriforce Growing Systems

us flag iconNASDAQ Capital Market

FAQ

Or unlock with your email

Or unlock with your email